Shuo Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuo Li has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Wenyuan Li
51 shared publications- Steven M. Dubinett
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
34 shared publications - Bin Liu
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
33 shared publications - Kostyantyn Krysan
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
32 shared publications - Edward Brian Garon
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
26 shared publications - Mary L. Stackpole
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA
25 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial
Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), but resistance to these therapies is common. We report here results from a phase I trial combining intratumoral injection of a CCL21-expressing dendritic cell (CCL21-DC) vaccine with pembrolizumab in patients with advanced non-small cell lung cancer (ClinicalTrials.gov identifier: NCT03546361). The primary objectives were to determine the maximum administered dose (MAD) in the dose escalation phase and the objective response rate (ORR) in the dose expansion. Eleven patients were enrolled in the dose escalation cohort, and 12 patients were treated in the dose expansion cohort at the MAD of 3 ×10 7 cells/injection. The trial did not meet its primary endpoint for ORR as no objective responses were observed, though 36.8% of patients achieved a best response of stable disease. The combination therapy was well tolerated. Post-hoc analyses of longitudinal biopsies revealed that the therapy increased tumor infiltration by CD4+ T cells and novel T cell clones. Disease stability was associated with increased T cell receptor diversity and greater expansion of novel clones following therapy. However, many novel clones failed to persist over time, and immunosuppressive myeloid signaling signatures were identified across time points. Our findings overall demonstrated that CCL21-DC vaccination combined with pembrolizumab can promote T cell infiltration, but this did not translate into meaningful clinical efficacy, potentially due to limited tumor specificity of the T cell response and an inability to fully reprogram the tumor microenvironment.
- 4 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Open AccessA CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial
Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), but resistance to these therapies is common. We report here results from a phase I trial combining intratumoral injection of a CCL21-expressing dendritic cell (CCL21-DC) vaccine with pembrolizumab in patients with advanced non-small cell lung cancer (ClinicalTrials.gov identifier: NCT03546361). The primary objectives were to determine the maximum administered dose (MAD) in the dose escalation phase and the objective response rate (ORR) in the dose expansion. Eleven patients were enrolled in the dose escalation cohort, and 12 patients were treated in the dose expansion cohort at the MAD of 3 ×10 7 cells/injection. The trial did not meet its primary endpoint for ORR as no objective responses were observed, though 36.8% of patients achieved a best response of stable disease. The combination therapy was well tolerated. Post-hoc analyses of longitudinal biopsies revealed that the therapy increased tumor infiltration by CD4+ T cells and novel T cell clones. Disease stability was associated with increased T cell receptor diversity and greater expansion of novel clones following therapy. However, many novel clones failed to persist over time, and immunosuppressive myeloid signaling signatures were identified across time points. Our findings overall demonstrated that CCL21-DC vaccination combined with pembrolizumab can promote T cell infiltration, but this did not translate into meaningful clinical efficacy, potentially due to limited tumor specificity of the T cell response and an inability to fully reprogram the tumor microenvironment.
- Open Access
- 6 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123  (15)
Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test
Plasma cell-free DNA (cfDNA), originating from multiple organs, holds significant potential for noninvasive diagnostics and prognostics. Current cfDNA methylation assays primarily focus on single clinical indications by targeting specific genomic loci. In contrast, comprehensive profiling of cfDNA methylome can enable simultaneous detection of multiple diseases by capturing organ-specific methylation signatures, thereby offering a holistic view of health, when disease etiology is unclear or when conventional biochemical diagnostics are unavailable. However, deep sequencing required for sensitive detection of methylation abnormalities remains prohibitively expensive, limiting widespread clinical use. To overcome this barrier, we developed MethylScan , a highly cost-effective approach for cfDNA methylome sequencing. We demonstrated its broad clinical utility in a cohort of 1,061 individuals across diverse applications, including multicancer detection in general population, liver cancer surveillance in high-risk individuals, liver disease classification, identification of organ abnormalities, and race prediction from cfDNA. In multicancer detection (liver, lung, ovarian, and stomach cancers), MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3% (95% CI: 58.9 to 67.9%) at 98.0% specificity for all cancer stages. For early-stage cancers, the AUROC was 0.916 (95% CI: 0.890 to 0.940), with 55.3% sensitivity (95% CI: 49.1 to 62.1%) at the same specificity. In liver cancer surveillance, MethylScan achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.
- 6 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123  (15)
Open AccessToward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test
Plasma cell-free DNA (cfDNA), originating from multiple organs, holds significant potential for noninvasive diagnostics and prognostics. Current cfDNA methylation assays primarily focus on single clinical indications by targeting specific genomic loci. In contrast, comprehensive profiling of cfDNA methylome can enable simultaneous detection of multiple diseases by capturing organ-specific methylation signatures, thereby offering a holistic view of health, when disease etiology is unclear or when conventional biochemical diagnostics are unavailable. However, deep sequencing required for sensitive detection of methylation abnormalities remains prohibitively expensive, limiting widespread clinical use. To overcome this barrier, we developed MethylScan , a highly cost-effective approach for cfDNA methylome sequencing. We demonstrated its broad clinical utility in a cohort of 1,061 individuals across diverse applications, including multicancer detection in general population, liver cancer surveillance in high-risk individuals, liver disease classification, identification of organ abnormalities, and race prediction from cfDNA. In multicancer detection (liver, lung, ovarian, and stomach cancers), MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3% (95% CI: 58.9 to 67.9%) at 98.0% specificity for all cancer stages. For early-stage cancers, the AUROC was 0.916 (95% CI: 0.890 to 0.940), with 55.3% sensitivity (95% CI: 49.1 to 62.1%) at the same specificity. In liver cancer surveillance, MethylScan achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.
- Open Access
- 5 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1) , 1388
Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis
- 5 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1) , 1388
Open AccessAuthor Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Tumor copy number variations identified from 106 cfDNA samples for model training and cross-validation
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Tumor copy number variations identified from 106 cfDNA samples for model training and cross-validation
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Tumor copy number variations identified from 27 cfDNA samples for independent validation
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Tumor copy number variations identified from 27 cfDNA samples for independent validation
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Clinical information of the tissue and blood samples
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Clinical information of the tissue and blood samples
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Fragment-based marker discovery between LUAD and LUSC
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Fragment-based marker discovery between LUAD and LUSC
- Open Access
- 29 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Tumor copy number variations identified from 27 cfDNA samples for independent validation
- 29 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Tumor copy number variations identified from 27 cfDNA samples for independent validation
- Open Access
- 29 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Fragment-based marker discovery between LUAD and LUSC
- 29 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Fragment-based marker discovery between LUAD and LUSC
- Open Access
- 29 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Clinical information of the tissue and blood samples
- 29 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Clinical information of the tissue and blood samples